Patients who developed AD had an overall higher incidence of comorbidities but surprisingly, had a significantly lower incidence of obesity in both metformin and insulin populations compared to patients who did not develop AD. This evidence concerns the gene INS and obesity due to melanocortin 4 receptor deficiency.